Evidence map›Paper›PMID 27359253›Full record

ArticleJournal of thrombosis and haemostasis : JTH2016

Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

A B Ozel, B McGee, D Siemieniak, P M Jacobi, S L Haberichter, L C Brody, J L Mills, A M Molloy, D Ginsburg, J Z Li and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Thrombotic risk determined byResearch and practice in thrombosis and haemostasis · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The commonBlood advances · 2018
    Article
  9. Article
  10. Review
  11. Review
  12. Genetic variants inBlood advances · 2017
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

A B OzelHuman Genetics, University of Michigan, Ann Arbor, MI, USA.
B McGeeHoward Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA.
D SiemieniakHoward Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA.
P M JacobiThe Blood Center of Wisconsin, Milwaukee, WI, USA.
S L HaberichterThe Blood Center of Wisconsin, Milwaukee, WI, USA.
L C BrodyNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
J L MillsEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
A M MolloySchool of Medicine, Trinity College Dublin, Dublin, UK.
D GinsburgHuman Genetics, University of Michigan, Ann Arbor, MI, USA.
J Z LiHuman Genetics, University of Michigan, Ann Arbor, MI, USA.
K C DeschDepartment of Pediatrics and Communicable Disease, University of Michigan, Ann Arbor, MI, USA. kdesch@umich.edu.
Howard Hughes Medical Institute · USUniversity of Michigan–Ann Arbor · USNational Institutes of Health · USVersiti Blood Center of Wisconsin · USTrinity College London · GB

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
The contribution folate and vitamin B12 genes to disease.ZIAHG000167 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BRODY, LAWRENCE C · 2009 to 2025
$17.6M
MOLECULAR GENETIC STUDY OF VONWILLEBRAND FACTORR37HL039693 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GINSBURG, DAVID · 2001 to 2010
$3.7M
NICHD Health Research Board Of Ireland Neural Tube Defects StudyZIAHD002502 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI MILLS, JAMES · 2009 to 2022
$2.9M
Molecular Genetic Study of von Willebrand FactorR01HL039693 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GINSBURG, DAVID · 1989 to 2016
$2.4M
Identifying novel genetic risk factors for venous thromboembolism (VTE)R01HL112642 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GINSBURG, DAVID, LI, JUN · 2012 to 2015
$1.5M
Howard Hughes Medical InstituteNHLBI NIH HHS P01 HL081588NHLBI NIH HHS R01 HL039693NHLBI NIH HHS R01 HL112642NHLBI NIH HHS R37 HL039693
6 · The paper itself

Abstract

unlabelledEssentials Variants at ABO, von Willebrand Factor (VWF) and 2q12 contribute to the variation in plasma in VWF. We performed a genome-wide association study of plasma VWF propeptide in 3,238 individuals. ABO, VWF and 2q12 loci had weak or no association or linkage with plasma VWFpp levels. VWF associated variants at ABO, VWF and 2q12 loci primarily affect VWF clearance rates. SUMMARY: Background Previous studies identified common variants at the ABO and VWF loci and unknown variants in a chromosome 2q12 linkage interval that contributed to the variation in plasma von Willebrand factor (VWF) levels. Whereas the association with ABO haplotypes can be explained by differential VWF clearance, little is known about the mechanisms underlying the association with VWF single-nucleotide polymorphisms (SNPs) or with variants in the chromosome 2 linkage interval. VWF propeptide (VWFpp) and mature VWF are encoded by the VWF gene and secreted at the same rate, but have different plasma half-lives. Therefore, comparison of VWFpp and VWF association signals can be used to assess whether the variants are primarily affecting synthesis/secretion or clearance. Methods We measured plasma VWFpp levels and performed genome-wide linkage and association studies in 3238 young and healthy individuals for whom VWF levels had been analyzed previously. Results and conclusions Common variants in an intergenic region on chromosome 7q11 were associated with VWFpp levels. We found that ABO serotype-specific SNPs were associated with VWFpp levels in the same direction as for VWF, but with a much lower effect size. Neither the association at VWF nor the linkage on chromosome 2 previously reported for VWF was observed for VWFpp. Taken together, these results suggest that the major genetic factors affecting plasma VWF levels, i.e. variants at ABO, VWF and a locus on chromosome 2, operate primarily through their effects on VWF clearance.

Indexed as

ABO Blood-Group SystemAdolescentAdultChromosome MappingChromosomes, Human, Pair 2FemaleGenetic LinkageGenetic VariationGenome-Wide Association StudyGenotypeHaplotypesHumansMalePhenotypeProtein Precursorsvon Willebrand DiseasesABO Blood-Group SystemProtein Precursorsvon Willebrand Factorgenetic linkage analysisgenome-wide association studyvenous thromboembolismvon Willebrand diseasevon Willebrand factor

Identifiers

PMID27359253
PMCPMC5035595
OpenAlexW2469940159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.